Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
MDR-TB most commonly develops in the course of TB treatment, [5] and is most commonly due to doctors giving inappropriate treatment, or patients missing doses or failing to complete their treatment. Because MDR tuberculosis is an airborne pathogen, persons with active, pulmonary tuberculosis caused by a multidrug-resistant strain can transmit ...
M. tuberculosis is able to reproduce inside the macrophage and will eventually kill the immune cell. The primary site of infection in the lungs, known as the Ghon focus, is generally located in either the upper part of the lower lobe, or the lower part of the upper lobe. [13] Tuberculosis of the lungs may also occur via infection from the blood ...
Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]
Extensively drug resistant tuberculosis is tuberculosis that is resistant to isoniazid and rifampicin, any fluoroquinolone, and any of the three second line injectable TB drugs (amikacin, capreomycin, and kanamycin). [1] TDR-TB has been identified in three countries; India, Iran, and Italy. The term was first presented in 2006, in which it ...
For active tuberculosis it is used with other antimycobacterial medications. [1] For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB. [1] Rifabutin was approved for medical use in the United States in 1992. [1] It is on the World Health Organization's List of Essential Medicines. [3]